-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On September 1st a new study showed that new coronary antibodies can last up to four months in the body.
more than 90 percent of new crown patients in Iceland have increased antibody levels after diagnosis and then remained stable for up to four months, a new study showed, Reuters reported on Sept. 2.
the findings were published September 1 in the New England Journal of Medicine.
researchers tested antibody levels on more than 30,000 Icelanders to find out how many people in Iceland are infected with the new coronavirus and how well they are immune when they recover.
, about 1% of Iceland's population is infected with the new coronavirus.
56 per cent of those infected had been tested and confirmed infected by PCR laboratories, another 14 per cent had not previously been formally diagnosed but had been quarantined for exposure to the virus, and the remaining 30 per cent had antibody tests showing that they had previously been infected.
researchers report that 91 percent of the 1,215 infected people confirmed by PCR testing had antibody levels that rose in the first two months of diagnosis and remained stable two months later.
, the study focused only on a study from a country in Iceland, and the results may be different in other diverse parts of the world.
previous study, antibody levels in patients with neo-coronary pneumonia dropped sharply months after infection, raising questions about the duration of the immunity that the infection might provide.
, chief executive of deCode Genetics, the genetic analysis and testing company that conducted the study, said the new findings could have an impact on the risk of re-infection with new crown pneumonia and the durability of the new crown vaccine.
, published at the same time as the study, warned that it was unclear whether antibodies in recovering new crown patients would protect them from re-infection.
()